|
|||||
|
|
Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model |
|
| Authors: | Timothy P Burkholder Joshua R Clayton Mark E Rempala James R Henry John M Knobeloch David Mendel Johnathan A McLean Yan Hao David A Barda Eileen L Considine Mark T Uhlik Yuefeng Chen Liandong Ma Laura J Bloem Jacqueline K Akunda Denis J McCann Manuel Sanchez-Felix David K Clawson Michael M Lahn James J Starling |
| Institution: | 1. Discovery Chemistry Research and Technology, Eli Lilly and Company, Indianapolis, IN, USA 2. Oncology Drug Discovery, Eli Lilly and Company, Indianapolis, IN, USA 3. Lead Generation/Lead Optimization Biology, Eli Lilly and Company, Indianapolis, IN, USA 4. Non-clinical Toxicology, Eli Lilly and Company, Indianapolis, IN, USA 5. Drug Disposition, Eli Lilly and Company, Indianapolis, IN, USA 6. Preformulation, Eli Lilly and Company, Indianapolis, IN, USA 7. Structural Biology, Eli Lilly and Company, Indianapolis, IN, USA 8. Early Oncology Clinical Investigation, Eli Lilly and Company, Indianapolis, IN, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |